Eric W. Lewis

Emergency Medicine
6801 Brecksville Rd
Suite 20
Independence, OH 44131

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications

Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.

Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.

Journal: JAMA ophthalmology
Published: May 08, 2025

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

Journal: Blood advances
Published: April 30, 2025

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.

Journal: Cancer
Published: May 01, 2023

Phosphate Toxicity and Epithelial to Mesenchymal Transition.

Phosphate Toxicity and Epithelial to Mesenchymal Transition.

Journal: Advances in experimental medicine and biology
Published: March 15, 2022

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

Journal: Cancer
Published: March 17, 2021

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Journal: The Lancet. Oncology
Published: October 18, 2019
Showing 1-6 of 6

Last Updated: 09/26/2026